- 专利标题: Pharmaceutical formulation containing gelling agent
-
申请号: US14733618申请日: 2015-06-08
-
公开(公告)号: US09498456B2公开(公告)日: 2016-11-22
- 发明人: Curtis Wright , Benjamin Oshlack , Christopher Breder
- 申请人: Purdue Pharma L.P.
- 申请人地址: US CT Stamford US NJ Totowa US NC Wilson
- 专利权人: Purdue Pharma L.P.,The P.F. Laboratories, Inc.,Purdue Pharmaceuticals L.P.
- 当前专利权人: Purdue Pharma L.P.,The P.F. Laboratories, Inc.,Purdue Pharmaceuticals L.P.
- 当前专利权人地址: US CT Stamford US NJ Totowa US NC Wilson
- 代理机构: Lowenstein Sandler LLP
- 主分类号: A61K9/00
- IPC分类号: A61K9/00 ; A61K31/137 ; A61K9/20 ; A61K31/439 ; A61K31/485 ; A61K47/38 ; A61K47/36 ; A61K47/10 ; A61K45/06 ; A61K31/167 ; A61K31/192 ; A61K9/16 ; A61K47/26 ; A61K31/48 ; A61K9/48 ; A61K47/08 ; A61K9/50 ; A61K47/32 ; A61K9/08 ; A61K9/28 ; A61K47/12 ; A61K47/34 ; A61K9/06 ; A61K31/4458
摘要:
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
公开/授权文献
- US20150265602A1 Pharmaceutical Formulation Containing Gelling Agent 公开/授权日:2015-09-24
信息查询